The estimated Net Worth of Fred Graff is at least $16.7 Tausend dollars as of 31 May 2016. Fred Graff owns over 8,000 units of Recro Pharma Inc stock worth over $16,720 and over the last 9 years Fred sold REPH stock worth over $0.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Fred Graff REPH stock SEC Form 4 insiders trading
Fred has made over 1 trades of the Recro Pharma Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Fred bought 8,000 units of REPH stock worth $67,680 on 31 May 2016.
The largest trade Fred's ever made was buying 8,000 units of Recro Pharma Inc stock on 31 May 2016 worth over $67,680. On average, Fred trades about 1,143 units every 0 days since 2016. As of 31 May 2016 Fred still owns at least 8,000 units of Recro Pharma Inc stock.
You can see the complete history of Fred Graff stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Fred Graff's mailing address?
Fred's mailing address filed with the SEC is C/O RECRO PHARMA, INC., 490 LAPP ROAD, MALVERN, PA, 19355.
Insiders trading at Recro Pharma Inc
Over the last 11 years, insiders at Recro Pharma Inc have traded over $25,533,136 worth of Recro Pharma Inc stock and bought 3,055,820 units worth $22,429,197 . The most active insiders traders include Healthcare Master Fund Ltd ..., Investment Company, Inc. Awm und James E Deerfield Mgmt L.P..... On average, Recro Pharma Inc executives and independent directors trade stock every 31 days with the average trade being worth of $151,953. The most recent stock trade was executed by J David Jr Enloe on 15 March 2022, trading 512 units of REPH stock currently worth $1,004.
What does Recro Pharma Inc do?
Recro Pharma Inc. is a contract development and manufacturing organization (CDMO) with capabilities from early feasibility to commercial manufacturing. With an expertise in solving complex manufacturing problems, Recro is a leading CDMO providing oral solid dosage form development, end-to-end regulatory support, clinical and commercial manufacturing, and packaging and logistics services to the global pharmaceutical market.
What does Recro Pharma Inc's logo look like?
Complete history of Fred Graff stock trades at Recro Pharma Inc
Recro Pharma Inc executives and stock owners
Recro Pharma Inc executives and other stock owners filed with the SEC include:
-
Geraldine Henwood,
President, Chief Executive Officer, Director -
Ryan Lake,
Chief Financial Officer -
William Ashton,
Independent Director -
Wayne Weisman,
Independent Chairman of the Board -
Winston Churchill,
Independent Director -
Michael Berelowitz,
Independent Director -
Ryan D. Lake,
Chief Financial Officer -
Bryan Reasons,
Independent Director -
J. David Enloe Jr.,
Pres, CEO & Director -
Argot Partners,
IR Contact Officer -
Tim Bourque,
VP of Operations & Site Head of San Diego -
David Smithwick B.S.,
VP of Operations & Site Head of Gainesville -
Richard Sidwell Ph.D.,
VP & Chief Scientific Officer -
Marshall Rizzo M.B.A.,
Sr. VP & GM -
Randall J. Mack,
Sr. VP of Devel. -
Erica Raether M.A.,
VP of People, Culture & ESG -
William Hirschman,
VP of Sales & Marketing -
Matthew McKendry,
Director of Accounting -
Laura L. Parks,
Director -
Karen Flynn,
Director -
Vitalife Partners Ii Lp Scp,
10% owner -
Donna Nichols,
CAO/Controller -
Stewart Mc Callum,
Chief Medical Officer -
Randall Mack,
Senior VP, Development -
Fred Graff,
Chief Commercial Officer -
Capital Management, Llc Sto...,
10% owner -
James E Deerfield Mgmt L.P....,
-
Vitalife Partners (Israel) ...,
10% owner -
Alfred Altomari,
Director -
Healthcare Master Fund Ltd ...,
-
Diane Myers,
Senior VP-Reg./Quality -
Jyrki Mattila,
Executive VP, Business Dev. -
Michael Celano,
Chief Financial Officer -
Arnaud Ajdler,
Director -
Abraham Ludomirski,
Director -
Charles Garner,
CFO and Chief Business Officer -
J David Jr Enloe,
Chief Executive Officer -
James Charles Miller,
Director -
Investment Company, Inc. Awm,
10% owner